DeepMed Research

Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Phase 3

Completed

Conditions: Mucositis
Oral Complications of Radiation Therapy
Pain
Head and Neck Cancer

Interventions: Other: placebo
Drug: doxepin hydrochloride

First Posted Date: 2010-07-02

Last Posted Date: 2017-08-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 155

Registration Number: NCT01156142

Locations: 🇺🇸
Hurley Medical Center, Flint, Michigan, United States
🇺🇸
Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States
🇺🇸
Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States

and more 117 locations

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Phase 3

Conditions: Colorectal Cancer

Interventions: Drug: 5-fluorouracil
Drug: celecoxib
Other: placebo
Drug: oxaliplatin
Drug: leucovorin

First Posted Date: 2010-06-24

Last Posted Date: 2022-03-22

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 2527

Registration Number: NCT01150045

Locations: 🇺🇸
Mount Carmel Hospital East, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States

and more 836 locations

Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

Completed

Conditions: Lung Cancer

Interventions: Genetic: DNA methylation analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis

First Posted Date: 2010-06-09

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 99

Registration Number: NCT01139944

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Doxorubicin Hydrochloride
Drug: Procarbazine Hydrochloride
Drug: Vinblastine Sulfate
Drug: Dacarbazine
Drug: Cyclophosphamide
Drug: Etoposide phosphate
Drug: prednisone
Drug: Radiation Therapy
Radiation: Fludeoxyglucose F-18
Procedure: computed tomography
Procedure: Positron Emission Tomography

First Posted Date: 2010-05-28

Last Posted Date: 2021-06-14

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 164

Registration Number: NCT01132807

Locations: 🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
🇺🇸
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 92 locations

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Phase 2

Terminated

Conditions: Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: anti-thymocyte globulin
Biological: donor lymphocytes
Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: tacrolimus
Other: reduced-intensity transplant conditioning procedure
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2010-05-06

Last Posted Date: 2017-03-24

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 6

Registration Number: NCT01118013

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States

and more 7 locations

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: ABVD
Drug: BEACOPP
Radiation: radiation therapy

First Posted Date: 2010-05-06

Last Posted Date: 2021-12-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 101

Registration Number: NCT01118026

Locations: 🇺🇸
Iredell Memorial Hospital, Statesville, North Carolina, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 52 locations

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: letrozole
Drug: panobinostat
Genetic: RNA analysis
Genetic: microarray analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: enzyme-linked immunosorbent assay
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2010-04-16

Last Posted Date: 2017-06-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 28

Registration Number: NCT01105312

Locations: 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸
Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸
Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States

and more 167 locations

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Phase 3

Completed

Conditions: Chemotherapeutic Agent Toxicity
Colorectal Cancer
Neuropathy
Neurotoxicity

Interventions: Drug: calcium gluconate
Other: placebo
Drug: magnesium sulfate
Drug: oxaliplatin

First Posted Date: 2010-04-07

Last Posted Date: 2022-11-03

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 362

Registration Number: NCT01099449

Locations: 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States

and more 398 locations

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Triple-negative Breast Cancer

Interventions: Drug: brostallicin
Drug: cisplatin

First Posted Date: 2010-03-24

Last Posted Date: 2018-05-08

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 48

Registration Number: NCT01091454

Locations: 🇺🇸
Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States

and more 259 locations

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pixantrone dimaleate

First Posted Date: 2010-03-15

Last Posted Date: 2018-05-08

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 46

Registration Number: NCT01086605

Locations: 🇺🇸
Galesburg Clinic, PC, Galesburg, Illinois, United States
🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
Illinois CancerCare - Canton, Canton, Illinois, United States

and more 226 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy